Trofosfamide

Summary

Trofosfamide (CHEMBL462019) is a phase-3 clinical-stage small molecule (ATC L01AA07); indicated across 5 conditions including sarcoma and soft tissue sarcoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01AA07
• Indications: 5 conditions
• Clinical trials: 4
• Chemistry: 323.6 Da · C9H18Cl3N2O2P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL462019
Name	Trofosfamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65702
ATC	L01AA07
Molecular formula	C9H18Cl3N2O2P
Molecular weight	323.6
InChIKey	UMKFEPPTGMDVMI-UHFFFAOYSA-N

SMILES: C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl

IUPAC name: N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine

Also known as: A-4828, NSC-109723, Trofosfamida, Trofosfamide, Z-4828, Trifosfamide, SID92764496, trofosfamide, TROFOSFAMIDE

Patent coverage: 8,396 distinct patent families (36,103 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sarcoma	3	MONDO:0005089	EFO:0000691
soft tissue sarcoma	3	MONDO:0018078	EFO:1001968
neoplasm	3	MONDO:0005070	EFO:0000616
medulloblastoma	2	MONDO:0007959	EFO:0002939
melanoma	1	MONDO:0005105	EFO:0000756

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00749723	PHASE2/PHASE3	COMPLETED	Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
NCT00876031	PHASE3	COMPLETED	Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
NCT00204568	PHASE2	UNKNOWN	Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)
NCT01614301	PHASE1/PHASE2	UNKNOWN	Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).